Dr Narendhar Gokulanathan

Department of Medical Oncology and Hemato-Oncology,

Apollo Hospitals, Bannerghatta Road, Bangalore

Dr Vishwanath S.

Professor and Head of the Department,

Department of Medical Oncology and Hemato-Oncology

Apollo Hospitals, /bannerghatta road, Banglore

The phase III PATINA trial demonstrates that adding palbociclib to maintenance anti-HER2 therapy and endocrine therapy significantly prolongs progression-free survival (PFS) in patients with HER2-positive, hormone receptor–positive metastatic breast cancer who have not progressed after first-line induction therapy.

Study Design

PATINA was a randomized, open-label, international phase III trial evaluating the strategy of simultaneous targeting of HER2, estrogen receptor (ER), and CDK4/6 pathways. The rationale centered on preventing pathway crosstalk and delaying cross-resistance.

• Primary endpoint: Investigator-assessed PFS
• Secondary endpoints: ORR, OS, safety
• N = 518 across 8 countries (1:1 randomization)
• 261 patients received palbociclib

Eligible patients had HER2-positive metastatic breast cancer without progression following 4–8 cycles of chemotherapy combined with HER2-targeted therapy.

Patient Characteristics

At a median follow-up of 28 months, the trial met its primary endpoint:

• Median age: 53 years
• 62% postmenopausal
• 54% de novo metastatic disease
• 73.6% visceral involvement
• Asymptomatic CNS metastases permitted

Notably, 94% received dual anti-HER2 therapy (trastuzumab + pertuzumab), and approximately 91% received an aromatase inhibitor. Nearly 70% achieved a partial or complete response to induction therapy. Median follow-up was 53.5 months.

Efficacy Outcomes

The trial met its primary endpoint with clinical and statistical significance:

• Median PFS:
  1. 44.3 months (palbociclib arm)
  2. 29.1 months (control arm)
• Hazard ratio for progression or death: 0.75 (95% CI, 0.59–0.96; P = .02)
• Confirmed objective response rate:
  1. ● 32.9% vs 24.8%
• Overall survival data remain immature (HR 0.89).

Safety

• Grade ≥3 adverse events:
  1. 79.7% (palbociclib)
  2. 30.6% (control)
• Grade 4 adverse events:
  1. 10% vs 3.6%

Neutropenia was the predominant toxicity; G-CSF support was prohibited per protocol.
Dose reductions occurred in 58% of patients, typically early in therapy.
18% discontinued palbociclib due to toxicity.
No treatment-related deaths were reported.

Interpretation

PATINA selected patients who demonstrated sensitivity to induction therapy, effectively enriching for endocrine- and HER2-responsive disease biology. In this favorable subgroup, the addition of palbociclib significantly extended PFS, supporting intensified maintenance therapy as a strategy.

However, several considerations remain:

• Open-label design with investigator assessment introduces potential bias in PFS measurement.
• Patients with aggressive or induction-refractory disease were excluded, limiting generalizability.
• ADC sequencing (eg, emerging data from DB-09) may influence future treatment algorithms.
• No predictive biomarker currently identifies which patients derive maximal benefit.

Quality-of-life outcomes were not formally reported in this study and warrant attention given the high rates of neutropenia and dose modification.

Implications for Practice

PATINA establishes a new maintenance strategy for HER2+/HR+ metastatic breast cancer in patients who respond to first-line induction therapy. For appropriate patients, it offers:

• A chemotherapy-free oral maintenance option
• Durable PFS benefit
• A biologically rational triplet targeting approach

Relevance in the Indian Context

While the Indian population comprised ~2% of the study cohort, several practical considerations apply:

• Palbociclib generics improve accessibility compared with other CDK4/6 inhibitors.
• Patients able to afford biosimilar HER2-targeted therapy may also access palbociclib, though financial disparities may widen.
• Regular hematologic monitoring increases out-of-pocket expenditure and clinic visits.
• With insurance support and telemedicine follow-up, the regimen is feasible in routine practice.

In HER2-driven, low hormone receptor–positive tumors or in patients with intracranial disease, tucatinib-based maintenance strategies may be preferable.